A radiologic-pathologic study of the histopathologic variants of ameloblastomas and their proliferation indices

OBJECTIVES

This study aimed to analyze the clinicoradiologic features and Ki-67 proliferation indices between the histopathologic variants of ameloblastomas (ABs) for possible associations.

STUDY DESIGN

The diagnosis and histopathologic variant were confirmed for all cases by experienced Oral and Maxillofacial Pathologists. Immunohistochemistry for Ki-67 was performed on the most representative formalin-fixed paraffin-embedded tissue block. Demographic, clinical data and radiologic features were analyzed from patient records and available radiographic examinations. The investigators were blinded to the histopathologic variant and proliferation index when the clinicoradiologic features were assessed.

RESULTS

The current study included 116 cases of AB in the final sample. The indolent behavior of the unicystic variant was supported by their low proliferation index and slow growth paired with low frequencies of cortical destruction, loss of teeth, root resorption, and encroachment on anatomical structures. In contrast, the comparatively high proliferation index of the plexiform variant correlated with their fast growth and pain. Furthermore, high radiologic frequencies of cortical destruction, loss of teeth, and encroachment of surrounding anatomical structures supported their more aggressive clinical course.

CONCLUSION

Statistically significant differences were noted between certain variants and Ki-67, location, borders, locularity, and cortical destruction, providing better insight into their biological behavior.

The dilemma of extensive unilocular radiolucent lesions of the jaws - value of immunohistochemistry as a diagnostic marker and prognostic Indicator

INTRODUCTION

Large Unilocular radiolucent lesions of the jaws often present a dilemma to both, the Oral Pathologist and the Maxillofacial surgeon with regards to their accurate diagnosis as well as their most appropriate treatment modality. A precise identification as to whether the lesion is a cyst or a tumor is imperative before any treatment is instituted. Once the correct diagnosis and likely prognosis are established, a management protocol can be planned which will completely eliminate the lesion, while at the same time, ensure least possible morbidity for the patient, such as pathological jaw fractures, persisting neurological deficits, esthetic deformity, functional debility, recurrence/persistence of the lesion, etc. AIM & OBJECTIVES: To establish the value of Immunohistochemistry (IH) as a Diagnostic marker and Prognostic indicator for extensive Unilocular radiolucent lesions of the jaws. To assess its role as an adjunct to Histopathological Examination (HPE) in distinguishing Odontogenic tumours from the cysts, by identifying the former using IH Tumor Markers; and in aiding in selection of the most appropriate and effective treatment option for each of such ambiguous lesions, based on their prognosis as indicated by the expression of lH Cell Proliferation Markers.

MATERIALS AND METHOD

Thirty cases of large Unilocular Radiolucent lesions of the jaws (Maxilla/Mandible) were managed over a period of three years. Histopathological examination (HPE) and Immunohistochemical (IH) analysis were carried out of the biopsy specimens in all the cases. Calretinin, an Immunohistochemical Tumor marker, was used to distinguish between Odontogenic cysts and tumours. Ki-67 and Proliferating Cell Nuclear Antigen (PCNA), Immunohistochemical Cell Proliferation markers, provided information on the aggressive potential of the lesions. On the basis of the above information, an appropriate management protocol was established for each of these different lesions. Nerve sparing enucleation and curettage was employed for the established cases of Odontogenic Cysts; Enucleation and curettage, peripheral ostectomy, followed by chemical cauterization was employed for the Unicystic Ameloblastomas and other Odontogenic tumours with a low Ki-67 and PCNA Proliferation Index (PI)/Labelling index (LI ≤ 3); Marginal resection was carried out for the tumours with a higher Labelling Index (LI >3 ≤5), and Segmental resection (including partial/complete Maxillectomy, Hemimandibulectomy with/without disarticulation) for the aggressive pathologies with high Labelling Index (LI > 5).

RESULTS

Of the thirty cases of large Unilocular radiolucent lesions of the Maxilla and Mandible, thirteen were diagnosed as Dentigerous cysts, one as Dentigerous cyst showing Ameloblastomatous transformation; two as Unicystic Ameloblastomas, one as the Mural variant of Unicystic Ameloblastoma; four as Follicular Ameloblastomas, two as Plexiform Ameloblastomas; four as Acanthomatous Ameloblastomas; one as Ameloblastic Fibroma and two as Adenomatoid Odontogenic Tumours. The predictive and prognostic indication of the Immunohistochemical markers correlated well with the post treatment findings.

CONCLUSION

In cases of extensive Unilocular lesions of the jaws, where ambiguity often exists in both diagnosis and appropriate treatment plan to be employed, Immunohistochemistry can serve as an invaluable tool in establishing the precise diagnosis, guiding the treatment plan, as well as indicating the likely prognosis of these lesions.

Immunohistochemical biomarkers in ameloblastomas

Ameloblastoma is an aggressive odontogenic tumour, which is locally invasive and highly recurrent. Studies show that ameloblastoma is a benign odontogenic neoplasia, being relatively rare and occasionally presenting behaviour of malignant lesions. In addition to these particularities, the histological diagnosis of ameloblastoma can be challenging when the tumour shows high rates of mitosis, absence of nuclear pleomorphism, basilar hyperplasia and neural invasion. In order to help in the diagnosis, prognosis and treatment of this neoplasia, some immunohistochemical markers were shown to be associated with tumoural epithelium. The identification of these markers as well as of their association with clinical signs can be useful to elaborate more efficient treatment strategies and to control this pathology, including improvement of the quality of life of patients affected by this neoplasia. This article aims to review some markers associated with specific molecular pathways, bone remodelling, cell proliferation, apoptosis, cell signalling and tumour suppression.

EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence

Background

Ameloblastoma is an odontogenic neoplasm characterized by local invasiveness and tendency towards recurrence.

Aims

Studying the role played by EGFR, CD10 and Ki67 in the recurrence of ameloblastoma.

Methods

This study was carried out on 22 retrospective cases of mandibular ameloblastoma from the period from Jan 2002 to Jan 2008 with follow up period until Jan 2011 (3 to 8 years follow up peroid). Archival materials were obtained from pathology department, Mansoura university. Paraffin sections of tumor tissue from all cases were submitted for routine H&E stains and immunohistochemistry using EGFR, CD10 and Ki67 monoclonal antibodies. Statistical analysis using of clinical data for all patients, tumor type, EGFR, CD10 and Ki67 expression in relation to recurrence were evaluated.

Results

Among the 22 cases, 10 cases were males and 12 were females with sex ratio 1:1.2. Age ranged from 34 to 59 years old with a mean age 44.18 year. Five cases showed local recurrence within studied period and proved by biopsy. No statistically significant relation was found between local recurrence and patient age, tumor size, tumor type, EGFR expression. There was a significant relation between CD10 expression as well as Ki67 labelling index and recurrence (P value = 0.003, 0.000 respectively).

Conclusion

Evaluation of CD10 and Ki67 status together with conventional histological evaluation can help in providing more information about the biologic behavior of the tumor, while EGFR could be a target of an expanding class of anticancer therapies.

Since ameloblastomas are EGFR-positive tumors, anti-EGFR agents could be considered to reduce the size of large tumors and to treat unresectable tumors that are in close proximity to vital structures.

Virtual Slides

The virtual slide(s) for this article can be found here:

http://www.diagnosticpathology.diagnomx.eu/vs/1902106905645651

Review article: Current concepts of ameloblastoma pathogenesis

Ameloblastoma is a locally destructive and invasive tumour that can recur despite adequate surgical removal. Molecular studies have offered interesting findings regarding ameloblastoma pathogenesis. In the present review, the following topics are discussed regarding its molecular nature: clonality, cell cycle proliferation, apoptosis, tumour suppressor genes, ameloblastin and other enamel matrix proteins, osteoclastic mechanism and matrix metalloproteinases and other signalling molecules. It is clear from the literature reviewed that translational studies are necessary to identify prognostic markers of ameloblastoma behaviour and to establish new diagnostic tools to the differential diagnosis of unicystic from multicystic ameloblastoma. Finally, molecular biology studies are also important to develop more effective alternative approaches to the treatment of this aggressive odontogenic tumour.

Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas

Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic ameloblastomas (UA), and to study its possible correlation to their biological behavior. Immunohistochemical studies were performed for syndecan-1 (clone MI15) and Ki-67 (clone MIB-1) in 120 ameloblastomas (75 SA and 45 UA). The salient finding was that expression of syndecan-1 was related to the histological subtype of tumors, as there was a lower expression in SA (40.2%) as compared to UA (49.7%) (p<0.05). These findings did not correlate with Ki-67 expression, as this was similar in both types of ameloblastomas. Our results suggest that the reduced expression of syndecan-1 supports the view that SA has a more aggressive biological behavior than the UA. The lack of correlation between reduction of the syndecan-1 and Ki-67 index may be due to the different histomorphologies of both types of ameloblastoma, and more studies are necessary to better understand the role of this protein in the biological behavior of these tumors.